#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean
A little more than a year after Yescarta was approved as the first CAR-T for third-line therapy in large B-cell lymphoma, researchers are still trying to determine what the median overall survival rate for patients is. It hasn’t been reached.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.